Fenwick & West LLP advised Prelude Therapeutics on the deal. Prelude Therapeutics (NASDAQ: PRLD), a clinical-stage precision oncology company, announced its upsized public offering of 2,583,334…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
